JP2005532319A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005532319A5 JP2005532319A5 JP2004503481A JP2004503481A JP2005532319A5 JP 2005532319 A5 JP2005532319 A5 JP 2005532319A5 JP 2004503481 A JP2004503481 A JP 2004503481A JP 2004503481 A JP2004503481 A JP 2004503481A JP 2005532319 A5 JP2005532319 A5 JP 2005532319A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- formula
- halogen
- substituted
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 22
- 229910052736 halogen Inorganic materials 0.000 claims 18
- 125000005843 halogen group Chemical group 0.000 claims 10
- 150000002367 halogens Chemical class 0.000 claims 8
- -1 methanesulfonyloxy, trifluoromethanesulfonyloxy, ethanesulfonyloxy, 2,2,2-trifluoroethanesulfonyloxy, propanesulfonyloxy, isopropanesulfonyloxy, butanesulfonyloxy Chemical group 0.000 claims 7
- 125000005947 C1-C6 alkylsulfonyloxy group Chemical group 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 6
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 5
- 239000012038 nucleophile Substances 0.000 claims 5
- MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical group NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 claims 4
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical group O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims 4
- 229930024421 Adenine Natural products 0.000 claims 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 4
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 238000006798 ring closing metathesis reaction Methods 0.000 claims 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims 3
- 108091034117 Oligonucleotide Proteins 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- 229940113082 thymine Drugs 0.000 claims 3
- HWPZZUQOWRWFDB-UHFFFAOYSA-N 1-methylcytosine Chemical group CN1C=CC(N)=NC1=O HWPZZUQOWRWFDB-UHFFFAOYSA-N 0.000 claims 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims 2
- ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical group CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 claims 2
- ZKBQDFAWXLTYKS-UHFFFAOYSA-N 6-Chloro-1H-purine Chemical compound ClC1=NC=NC2=C1NC=N2 ZKBQDFAWXLTYKS-UHFFFAOYSA-N 0.000 claims 2
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical group NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 claims 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical group [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims 2
- 229960000643 adenine Drugs 0.000 claims 2
- 150000003934 aromatic aldehydes Chemical class 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 239000003638 chemical reducing agent Substances 0.000 claims 2
- 229940104302 cytosine Drugs 0.000 claims 2
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical group NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 claims 2
- 229960004413 flucytosine Drugs 0.000 claims 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 2
- 125000002346 iodo group Chemical group I* 0.000 claims 2
- 125000002524 organometallic group Chemical group 0.000 claims 2
- 239000003880 polar aprotic solvent Substances 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- YWWDBCBWQNCYNR-UHFFFAOYSA-N trimethylphosphine Chemical compound CP(C)C YWWDBCBWQNCYNR-UHFFFAOYSA-N 0.000 claims 2
- 229940035893 uracil Drugs 0.000 claims 2
- 229940075420 xanthine Drugs 0.000 claims 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- JYWKEVKEKOTYEX-UHFFFAOYSA-N 2,6-dibromo-4-chloroiminocyclohexa-2,5-dien-1-one Chemical compound ClN=C1C=C(Br)C(=O)C(Br)=C1 JYWKEVKEKOTYEX-UHFFFAOYSA-N 0.000 claims 1
- LMRDBJZQDUVCQH-UHFFFAOYSA-N 2-(1,3-dioxoisoindol-2-yl)acetaldehyde Chemical compound C1=CC=C2C(=O)N(CC=O)C(=O)C2=C1 LMRDBJZQDUVCQH-UHFFFAOYSA-N 0.000 claims 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims 1
- QWZDKYIWDGZVDK-JFGNBEQYSA-N [(3s,4r,5r)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)-4-methylsulfonyloxy-2-(methylsulfonyloxymethyl)oxolan-2-yl]methyl methanesulfonate Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](OS(C)(=O)=O)[C@H](N=[N+]=[N-])C(COS(C)(=O)=O)(COS(C)(=O)=O)O1 QWZDKYIWDGZVDK-JFGNBEQYSA-N 0.000 claims 1
- FGZFFVCJLAVVJY-ZIFCJYIRSA-N [(3s,4r,5r)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)-4-methylsulfonyloxy-2-(methylsulfonyloxymethyl)-3-phenylmethoxyoxolan-2-yl]methyl methanesulfonate Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](OS(C)(=O)=O)[C@H](OCC=2C=CC=CC=2)C(COS(C)(=O)=O)(COS(C)(=O)=O)O1 FGZFFVCJLAVVJY-ZIFCJYIRSA-N 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 150000008064 anhydrides Chemical class 0.000 claims 1
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 claims 1
- HUMNYLRZRPPJDN-KWCOIAHCSA-N benzaldehyde Chemical group O=[11CH]C1=CC=CC=C1 HUMNYLRZRPPJDN-KWCOIAHCSA-N 0.000 claims 1
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzenecarboxaldehyde Natural products O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 claims 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical group ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 150000002118 epoxides Chemical class 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Substances [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 claims 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 claims 1
- RCYFOPUXRMOLQM-UHFFFAOYSA-N pyrene-1-carbaldehyde Chemical compound C1=C2C(C=O)=CC=C(C=C3)C2=C2C3=CC=CC2=C1 RCYFOPUXRMOLQM-UHFFFAOYSA-N 0.000 claims 1
- FNRNHFMKSCPBDA-UHFFFAOYSA-N pyrene-1-carbonyl chloride Chemical compound C1=C2C(C(=O)Cl)=CC=C(C=C3)C2=C2C3=CC=CC2=C1 FNRNHFMKSCPBDA-UHFFFAOYSA-N 0.000 claims 1
- 125000004469 siloxy group Chemical group [SiH3]O* 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 0 C*1[C@](C*)(CN)*[C@](*)C1O Chemical compound C*1[C@](C*)(CN)*[C@](*)C1O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200200712 | 2002-05-08 | ||
| DKPA200201214 | 2002-08-16 | ||
| PCT/DK2003/000305 WO2003095467A1 (en) | 2002-05-08 | 2003-05-08 | Synthesis of locked nucleic acid derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005532319A JP2005532319A (ja) | 2005-10-27 |
| JP2005532319A5 true JP2005532319A5 (https=) | 2006-04-27 |
| JP4476802B2 JP4476802B2 (ja) | 2010-06-09 |
Family
ID=29421786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004503481A Expired - Lifetime JP4476802B2 (ja) | 2002-05-08 | 2003-05-08 | ロックト核酸誘導体の製造 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1501848B1 (https=) |
| JP (1) | JP4476802B2 (https=) |
| AT (1) | ATE369375T1 (https=) |
| AU (1) | AU2003222743B2 (https=) |
| CA (1) | CA2484526C (https=) |
| DE (1) | DE60315444T2 (https=) |
| DK (1) | DK1501848T3 (https=) |
| ES (1) | ES2290448T3 (https=) |
| WO (1) | WO2003095467A1 (https=) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE44779E1 (en) | 1997-03-07 | 2014-02-25 | Santaris Pharma A/S | Bicyclonucleoside and oligonucleotide analogues |
| AU2003225495B2 (en) | 2002-04-05 | 2009-01-15 | Roche Innovation Center Copenhagen A/S | Oligomeric compounds for the modulation HIF-1alpha expression |
| WO2004046160A2 (en) | 2002-11-18 | 2004-06-03 | Santaris Pharma A/S | Amino-lna, thio-lna and alpha-l-oxy-ln |
| US7713738B2 (en) | 2003-02-10 | 2010-05-11 | Enzon Pharmaceuticals, Inc. | Oligomeric compounds for the modulation of survivin expression |
| ATE443765T1 (de) | 2003-03-21 | 2009-10-15 | Santaris Pharma As | Analoga kurzer interferierender rna (sirna) |
| WO2005061710A1 (en) | 2003-12-23 | 2005-07-07 | Santaris Pharma A/S | Oligomeric compounds for the modulation of bcl-2 |
| MX2007005558A (es) | 2004-11-09 | 2008-01-31 | Santaris Pharma As | Oligonucleotidos de lna potentes para la inhibicion dela expresion de hif-1a. |
| WO2006050732A2 (en) | 2004-11-09 | 2006-05-18 | Santaris Pharma A/S | Lna oligonucleotides and the treatment of cancer |
| US9447138B2 (en) | 2004-11-09 | 2016-09-20 | Roche Innovation Center Copenhagen A/S | Potent LNA oligonucleotides for the inhibition of HIF-1a expression |
| US8071306B2 (en) | 2005-01-25 | 2011-12-06 | Merck Sharp & Dohme Corp. | Methods for quantitating small RNA molecules |
| WO2007107162A2 (en) | 2006-03-23 | 2007-09-27 | Santaris Pharma A/S | Small internally segmented interfering rna |
| SG10201406016SA (en) | 2006-04-03 | 2014-11-27 | Stella Aps | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
| EP2007888A2 (en) | 2006-04-03 | 2008-12-31 | Santaris Pharma A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
| EP2054415A1 (en) * | 2006-07-14 | 2009-05-06 | Santaris Pharma A/S | Adenosine receptor antagonists |
| US8470791B2 (en) | 2007-03-22 | 2013-06-25 | Santaris Pharma A/S | RNA antagonist compounds for the inhibition of Apo-B100 expression |
| DK2149605T3 (da) | 2007-03-22 | 2013-09-30 | Santaris Pharma As | Korte RNA antagonist forbindelser til modulering af det ønskede mRNA |
| CA2689602A1 (en) | 2007-06-06 | 2008-12-18 | Avi Biopharma, Inc. | Soluble her2 and her3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease |
| WO2009027978A1 (en) | 2007-08-30 | 2009-03-05 | Hadasit Medical Research Services & Development Ltd. | NUCLEIC ACID SEQUENCES COMPRISING NF-ϰB BINDING SITE WITHIN O(6)-METHYLGUANINE-DNA-METHYLTRANSFERASE (MGMT) PROMOTER REGION AND USES THEREOF FOR THE TREATMENT OF CANCER AND IMMUNE-RELATED DISORDERS |
| EP2195428B1 (en) | 2007-09-19 | 2013-12-11 | Applied Biosystems, LLC | SiRNA SEQUENCE-INDEPENDENT MODIFICATION FORMATS FOR REDUCING OFF-TARGET PHENOTYPIC EFFECTS IN RNAi, AND STABILIZED FORMS THEREOF |
| EP2623599B1 (en) | 2007-10-04 | 2019-01-02 | Roche Innovation Center Copenhagen A/S | Micromirs |
| CA2717792A1 (en) | 2008-03-07 | 2009-09-11 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microrna related diseases |
| WO2010012667A1 (en) | 2008-08-01 | 2010-02-04 | Santaris Pharma A/S | Micro-rna mediated modulation of colony stimulating factors |
| ES2599979T3 (es) | 2009-04-24 | 2017-02-06 | Roche Innovation Center Copenhagen A/S | Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón |
| EP2456870A1 (en) | 2009-07-21 | 2012-05-30 | Santaris Pharma A/S | Antisense oligomers targeting pcsk9 |
| WO2011105902A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 8-beta (c8-beta) and uses thereof |
| WO2011105901A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 9 (c9) and uses thereof |
| WO2011105900A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 8-alpha (c8-alpha) and uses thereof |
| EP2542678B1 (en) | 2010-03-04 | 2017-04-12 | InteRNA Technologies B.V. | A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS THERAPEUTIC USES IN CANCER ASSOCIATED WITH EMT |
| EP2591106A1 (en) | 2010-07-06 | 2013-05-15 | InteRNA Technologies B.V. | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway |
| GB201012418D0 (en) | 2010-07-23 | 2010-09-08 | Santaris Pharma As | Process |
| EP2474617A1 (en) | 2011-01-11 | 2012-07-11 | InteRNA Technologies BV | Mir for treating neo-angiogenesis |
| WO2013011122A1 (en) * | 2011-07-21 | 2013-01-24 | Rhodia Operations | Guar hydroxypropyltrimethylammonium chloride and uses thereof in hair treatment compositions |
| EP3369818B1 (en) | 2011-12-22 | 2021-06-09 | InteRNA Technologies B.V. | Mirna for treating head and neck cancer |
| SG10201913554YA (en) | 2011-12-22 | 2020-03-30 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| EP2917348A1 (en) | 2012-11-06 | 2015-09-16 | InteRNA Technologies B.V. | Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway |
| WO2014108759A1 (en) | 2013-01-14 | 2014-07-17 | Pierfrancesco Tassone | INHIBITORS OF miRNAs 221 AND 222 FOR ANTI-TUMOR ACTIVITY IN MULTIPLE MYELOMA |
| US9428537B2 (en) | 2013-03-15 | 2016-08-30 | The Board Of Trustees Of The Leland Stanford Junior University | tRNA derived small RNAs (tsRNAs) involved in cell viability |
| HUE048738T2 (hu) | 2013-06-27 | 2020-08-28 | Roche Innovation Ct Copenhagen As | Antiszensz oligomerek és konjugátumok, amelyek a PCK9-t célozzák meg |
| GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
| AU2015327836B2 (en) | 2014-10-03 | 2021-07-01 | Cold Spring Harbor Laboratory | Targeted augmentation of nuclear gene output |
| WO2016128583A2 (en) | 2015-02-15 | 2016-08-18 | Ribo Task Aps | Acyl-amino-lna and/or hydrocarbyl-amino-lna oligonucleotides |
| TW201718618A (zh) * | 2015-09-18 | 2017-06-01 | 田邊三菱製藥股份有限公司 | 架橋型核酸ＧｕＮＡ，其製造方法，及中間體化合物 |
| CN108603230A (zh) | 2015-10-09 | 2018-09-28 | 南安普敦大学 | 基因表达的调节与蛋白质表达失调的筛选 |
| WO2017106377A1 (en) | 2015-12-14 | 2017-06-22 | Cold Spring Harbor Laboratory | Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome |
| US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
| US11390867B2 (en) | 2016-04-29 | 2022-07-19 | Nanyang Technological University | G-quadruplex-containing antisense oligonucleotides |
| EP3494219A1 (en) | 2016-08-03 | 2019-06-12 | Aalborg Universitet | ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS |
| KR102318434B1 (ko) | 2017-08-25 | 2021-11-01 | 스톡 테라퓨틱스, 인크. | 병태 및 질환 치료용 안티센스 올리고머 |
| CN111566212A (zh) | 2017-11-03 | 2020-08-21 | 因特尔纳技术有限公司 | miRNA分子，等同物，安塔够妙或其来源用于治疗和/或诊断与神经元缺陷相关的病症和/或疾病或用于神经元生成和/或再生 |
| JP2021513508A (ja) | 2018-02-12 | 2021-05-27 | インテアールエヌエー テクノロジーズ ビー．ヴイ．ＩｎｔｅＲＮＡ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｂ．Ｖ． | 抗がんマイクロｒｎａ及びその脂質製剤 |
| CA3099280A1 (en) | 2018-05-04 | 2019-11-07 | Stoke Therapeutics, Inc. | Methods and compositions for treatment of cholesteryl ester storage disease |
| AU2020227825B2 (en) | 2019-02-27 | 2026-03-26 | Stoke Therapeutics, Inc. | Antisense oligomers for treatment of conditions and diseases |
| IT201900017234A1 (it) | 2019-09-25 | 2021-03-25 | Int Centre For Genetic Engineering And Biotechnology | Anti-miRNA per il trattamento del leiomioma |
| CN115867657A (zh) | 2020-05-11 | 2023-03-28 | 斯托克制药公司 | 用于治疗疾患和疾病的opa1反义寡聚物 |
| CN117280030A (zh) | 2021-02-12 | 2023-12-22 | 梅兰德制药公司 | 用于治疗缺氧和缺血相关病症的药剂、组合物和方法 |
| WO2022200633A1 (en) | 2021-03-26 | 2022-09-29 | Neumirna Therapeutics Aps | Microrna-27b inhibitors |
| AU2022245292A1 (en) | 2021-03-26 | 2023-10-12 | Neumirna Therapeutics Aps | Microrna-134 inhibitors |
| WO2022254021A1 (en) | 2021-06-04 | 2022-12-08 | Neumirna Therapeutics Aps | Antisense oligonucleotides targeting adenosine kinase |
| CN118202050A (zh) | 2021-08-17 | 2024-06-14 | 韩国科学技术院 | 靶向cav3.1基因的反义寡核苷酸及其用途 |
| EP4388096A1 (en) | 2021-08-19 | 2024-06-26 | Neumirna Therapeutics ApS | Antisense oligonucleotides targeting adenosine kinase |
| EP4332239A1 (en) | 2022-08-30 | 2024-03-06 | Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. | Mir-based assay for gastro-entero-pancreatic neuroendocrine tumor diagnosis and prognosis |
| EP4450626A1 (en) | 2023-04-21 | 2024-10-23 | IFOM - Istituto Fondazione di Oncologia Molecolare ETS | Fnip2 inhibitors for treating ataxia telangiectasia |
| WO2025015676A1 (zh) * | 2023-07-21 | 2025-01-23 | 瑞孚医药科技（广州）有限公司 | 碳环核苷、寡核苷酸及其制备方法和医药用途 |
| EP4512899A1 (en) | 2023-08-23 | 2025-02-26 | Lipigon Pharmaceuticals AB | Angptl4 aso compositions for treatment of atherosclerosis in humans |
| WO2026068729A1 (en) | 2024-09-26 | 2026-04-02 | Neumirna Therapeutics Aps | Antimir-27b for treatment of parkinson's disease |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7053207B2 (en) * | 1999-05-04 | 2006-05-30 | Exiqon A/S | L-ribo-LNA analogues |
| JP4413493B2 (ja) * | 2000-10-04 | 2010-02-10 | サンタリス ファーマ アー／エス | プリンｌｎａ類似体の改善された合成方法 |
-
2003
- 2003-05-08 AU AU2003222743A patent/AU2003222743B2/en not_active Expired
- 2003-05-08 JP JP2004503481A patent/JP4476802B2/ja not_active Expired - Lifetime
- 2003-05-08 CA CA002484526A patent/CA2484526C/en not_active Expired - Lifetime
- 2003-05-08 EP EP03718663A patent/EP1501848B1/en not_active Expired - Lifetime
- 2003-05-08 AT AT03718663T patent/ATE369375T1/de not_active IP Right Cessation
- 2003-05-08 DK DK03718663T patent/DK1501848T3/da active
- 2003-05-08 WO PCT/DK2003/000305 patent/WO2003095467A1/en not_active Ceased
- 2003-05-08 ES ES03718663T patent/ES2290448T3/es not_active Expired - Lifetime
- 2003-05-08 DE DE60315444T patent/DE60315444T2/de not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005532319A5 (https=) | ||
| AU636108B2 (en) | Therapeutic 6-substituted purine carbocyclic nucleosides and pharmaceutically acceptable derivatives thereof | |
| CN1290841C (zh) | 核苷类似物的非对映选择合成方法 | |
| US6175008B1 (en) | Processes for preparing substituted 1,3-oxathiolanes with antiviral properties | |
| WO2012043730A1 (ja) | モルホリノ核酸誘導体 | |
| PT1155695E (pt) | Utilização de um análogo do nucleósido 1,3-oxatiolano no fabrico de um medicamento para administração específica | |
| CN1285843A (zh) | 化合物 | |
| US6600044B2 (en) | Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers | |
| PT90159B (pt) | Processo para a preparacao de bis(hidroximetil) ciclobutil purinas e pirimidinas | |
| EP0674634A1 (en) | Process for preparing substituted 1,3-oxathiolanes with antiviral properties | |
| EP0521923B1 (en) | Process for producing nucleosides, and analogs therof | |
| EP0369583B1 (en) | Chemical process for the preparation of purine derivatives | |
| JP2017522343A (ja) | ホスホルアミデート類の合成 | |
| CN101918394A (zh) | 制备取代的1,3-氧硫杂环戊烷的方法 | |
| US8399655B2 (en) | Process and methods for the preparation of optically active cis-2-hydroxymethyl-4-(cytosin-1′-yl)-1,3-oxathiolane or pharmaceutically acceptable salts thereof | |
| CN1036712C (zh) | 抗病毒剂[1R-(1α，2β，3α)]-2-氨基-9-[2，3-双(羟甲基)环丁基]-1，9-二氢-6H-嘌呤-6-酮的制备方法 | |
| JP5690731B2 (ja) | ２，４−二置換１，３−オキサチオランヌクレオシドの鏡像異性体分割 | |
| EP0479822B1 (en) | Therapeutic nucleosides | |
| CN101918416A (zh) | 制备取代的1,3-氧硫杂环戊烷,尤其是拉米夫定的方法和中间体 | |
| CN101142211B (zh) | 制备光学活性顺式-2-羟甲基-4-(胞嘧啶-1’-基)-1,3-氧硫杂戊环或其药物可接受盐的工艺和方法 | |
| JP2002293792A (ja) | ヌクレオシド又は糖のフッ素化誘導体の製造方法 | |
| CN1057652A (zh) | 一种制备取代的无环核苷及其有关中间体的方法 | |
| CN120957994A (zh) | 用于制备寡核苷酸类似物或其盐的中间体及其制备方法 | |
| BR112014008622B1 (pt) | Derivados de ciclopropano, seus métodos de preparação e seu uso | |
| JPH01100190A (ja) | ヌクレオシド類 |